Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Study Identifier
192024-085
CT.gov Identifier
NCT02676310
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Hair Loss - Other
    • Study Drug
  • Bimatoprost
    • Phase
    Phase 1
    Sex
    Male
    Age
    18 - 49 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year
    Exclusion Criteria:
    * History of Paget's disease, osteoporosis, or bone malignancy * History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures * Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study * Drug or alcohol abuse within 12 months * HIV positive * Received hair transplants or had scalp reductions * Use of hair weaves, hair extensions or wigs within 3 months * Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks

    Protocol Summary

    This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).

    Study Locations

    Location
    Status
    Location
    DermResearch, LLC
    Austin, Texas, United States, 78759
    Status
    Not applicable
    Location
    J&S Studies Inc.
    College Station, Texas, United States, 77845
    Status
    Not applicable
    Location
    E&R Research Foundation
    Lynchburg, Virginia, United States, 24501
    Status
    Not applicable